Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HMB-001

Small molecule

UUnknown Sponsor

HMB-001 is one of 8 small molecule programs targeting Asthenia. It is currently in development.

1

Indications

1

Total Trials

1

Active Trials

7

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstheniaActive, not recruiting

AstheniaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

14 competitors in Asthenia

#DrugCompanyPhaseTrials

Ritalin

Rysodeg

Rayos

RRoxane Laboratories

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Ranquilon

VValenta Pharm JSC

Prospekta

MMateria Medica Holding

Eptacog Alfa

HMB-001

UUnknown Sponsor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Active, not recruiting

Asthenia

NCT06211634

Clinical

Trials by Indication[1]

Asthenia1 trial

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Active, not recruiting·UUnknown Sponsor·Phase 1/2·NCT06211634·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HMB-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMB-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMB-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Unknown Sponsor company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUnknown Sponsor

Related News